GlassScriptPhysician profile
John C Liu
NPI 1255781274
$7,707.26
in general payments reported to CMS, 2019-2025
33 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $520 · 2022: $2,267 · 2023: $2,251 · 2024: $1,755 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,860 · Education: $60.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.92 |
| Education | $60.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,190.10 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $701.89 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $696.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $576.62 | 2022-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $482.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.66 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Amneal Pharmaceuticals LLC | $363.87 | 2022-2025 | Unithroid |
| Amgen INC. | $358.15 | 2022-2025 | Evenity, Prolia, Tepezza |
| Radius Health, INC. | $320.16 | 2023-2025 | Tymlos |
| Abbvie INC. | $272.60 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $233.91 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $209.57 | 2022-2025 | |
| Ascensia Diabetes Care US INC. | $206.67 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $185.52 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $174.18 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $146.59 | 2021-2024 | Afrezza |
| Merck Sharp & Dohme LLC | $146.48 | 2022-2023 | Steglujan, Steglatro |
| Novartis Pharmaceuticals Corporation | $131.18 | 2023-2025 | |
| Dexcom, INC. | $103.15 | 2024-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $101.31 | 2023-2024 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $89.15 | 2023-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $87.80 | 2023-2025 | Strensiq |
| Amarin Pharma, INC. | $82.15 | 2021-2022 | |
| Ibsa Pharma INC. | $67.88 | 2022-2024 | Tirosint, Licart, Tirosint |
| Grt US Holding, INC. | $67.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $60.11 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $58.96 | 2022-2023 | Omnipod |
| Ascendis Pharma Endocrinology INC | $52.10 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $47.72 | 2025 | Twiist |
| Medtronic, INC. | $45.12 | 2022-2023 | Minimed 780g |
| Antares Pharma, INC. | $20.65 | 2025 | Xyosted |
| Zealand Pharma US, INC. | $15.11 | 2021 | |
| Amryt Pharma Holdings LTD | $14.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.